Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Apoptosis

RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis

A Corrigendum to this article was published on 11 July 2012

Abstract

Evasion of apoptosis may contribute to poor treatment response in pediatric acute lymphoblastic leukemia (ALL), calling for novel treatment strategies. Here, we report that inhibitors of apoptosis (IAPs) at subtoxic concentrations cooperate with various anticancer drugs (that is, AraC, Gemcitabine, Cyclophosphamide, Doxorubicin, Etoposide, Vincristine and Taxol) to induce apoptosis in ALL cells in a synergistic manner as calculated by combination index and to reduce long-term clonogenic survival. Importantly, we identify RIP1 as a critical regulator of this synergism of IAP inhibitors and AraC that mediates the formation of a RIP1/FADD/caspase-8 complex via an autocrine/paracrine loop of tumor necrosis factor-α (TNFα). Knockdown of RIP1 abolishes formation of this complex and subsequent activation of caspase-8 and -3, mitochondrial perturbations and apoptosis. Similarly, inhibition of RIP1 kinase activity by Necrostatin-1 or blockage of TNFα by Enbrel inhibits IAP inhibitor- and AraC-triggered interaction of RIP1, FADD and caspase-8 and apoptosis. In contrast to malignant cells, IAP inhibitors and AraC at equimolar concentrations are non-toxic to normal peripheral blood lymphocytes or mesenchymal stromal cells. Thus, our findings provide first evidence that IAP inhibitors present a promising strategy to prime childhood ALL cells for chemotherapy-induced apoptosis in a RIP1-dependent manner. These data have important implications for developing apoptosis-targeted therapies in childhood leukemia.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Pui CH, Relling MV, Downing JR . Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535–1548.

    Article  CAS  Google Scholar 

  2. Stanulla M, Cario G, Meissner B, Schrauder A, Moricke A, Riehm H et al. Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group. Blood Cells Mol Dis 2007; 39: 160–163.

    Article  Google Scholar 

  3. Fulda S . Tumor resistance to apoptosis. Int J Cancer 2009; 124: 511–515.

    Article  CAS  Google Scholar 

  4. Fulda S . Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia. Br J Haematol 2009; 145: 441–454.

    Article  CAS  Google Scholar 

  5. Fulda S, Debatin KM . Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798–4811.

    Article  CAS  Google Scholar 

  6. Ashkenazi A . Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 2008; 19: 325–331.

    Article  CAS  Google Scholar 

  7. Kroemer G, Galluzzi L, Brenner C . Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99–163.

    Article  CAS  Google Scholar 

  8. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG . IAP-targeted therapies for cancer. Oncogene 2008; 27: 6252–6275.

    Article  CAS  Google Scholar 

  9. Eckelman BP, Salvesen GS, Scott FL . Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 2006; 7: 988–994.

    Article  CAS  Google Scholar 

  10. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689–700.

    Article  CAS  Google Scholar 

  11. Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P . RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ 2007; 14: 400–410.

    Article  CAS  Google Scholar 

  12. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007; 131: 669–681.

    Article  CAS  Google Scholar 

  13. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682–693.

    Article  CAS  Google Scholar 

  14. Wang L, Du F, Wang X . TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693–703.

    Article  CAS  Google Scholar 

  15. Hundsdoerfer P, Dietrich I, Schmelz K, Eckert C, Henze G . XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL. Pediatr Blood Cancer 2010; 55: 260–266.

    Article  Google Scholar 

  16. Wuchter C, Richter S, Oltersdorf D, Karawajew L, Ludwig WD, Tamm I . Differences in the expression pattern of apoptosis-related molecules between childhood and adult de novo acute myeloid leukemia. Haematologica 2004; 89: 363–364.

    CAS  Google Scholar 

  17. Fakler M, Loeder S, Vogler M, Schneider K, Jeremias I, Debatin KM et al. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009; 113: 1710–1722.

    Article  CAS  Google Scholar 

  18. Oost TK, Sun C, Armstrong RC, Al-Assaad AS, Betz SF, Deckwerth TL et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 2004; 47: 4417–4426.

    Article  CAS  Google Scholar 

  19. Chao B, Deckwerth TL, Furth PS, Linton SD, Spada AP, Ullman BR et al., inventors; Tetrapeptide Analogs, United States patent PCT/US2005/024700. 2006 16.02.

  20. Fulda S, Strauss G, Meyer E, Debatin KM . Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. Blood 2000; 95: 301–308.

    CAS  Google Scholar 

  21. Vogler M, Durr K, Jovanovic M, Debatin KM, Fulda S . Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 2007; 26: 248–257.

    Article  CAS  Google Scholar 

  22. Mohr A, Zwacka RM, Debatin KM, Stahnke K . A novel method for the combined flow cytometric analysis of cell cycle and cytochrome c release. Cell Death Differ 2004; 11: 1153–1154.

    Article  CAS  Google Scholar 

  23. Chou TC . The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC (ed). Synergism and antagonism in chemotherapy. Academic Press: San Diego, USA, 1991, pp 61–102.

    Google Scholar 

  24. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007; 12: 445–456.

    Article  CAS  Google Scholar 

  25. Ting AT, Pimentel-Muinos FX, Seed B . RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. Embo J 1996; 15: 6189–6196.

    Article  CAS  Google Scholar 

  26. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112–119.

    Article  CAS  Google Scholar 

  27. Degterev A, Hitomi J, Germscheid M, Ch’en IL, Korkina O, Teng X et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4: 313–321.

    Article  CAS  Google Scholar 

  28. Loeder S, Drensek A, Jeremias I, Debatin KM, Fulda S . Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis. Int J Cancer 2010; 126: 2216–2228.

    CAS  Google Scholar 

  29. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009; 69: 2425–2434.

    Article  CAS  Google Scholar 

  30. Vellanki SH, Grabrucker A, Liebau S, Proepper C, Eramo A, Braun V et al. Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia 2009; 11: 743–752.

    Article  CAS  Google Scholar 

  31. Loeder S, Zenz T, Schnaiter A, Mertens D, Winkler D, Dohner H et al. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res 2009; 69: 8977–8986.

    Article  CAS  Google Scholar 

  32. Fulda S . Inhibitor of apoptosis proteins in hematological malignancies. Leukemia 2009; 23: 467–476.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank C Hulford and M Luzzio (Pfizer Inc., Groton, CN) for providing IAP inhibitors and S Zhou (Ulm, Germany) for help with the analysis of TNFα levels. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft (to SF), José Carreras Leukämie-Stiftung (to SF), European Community (to SF and PV), IAP6/18 (to SF and PV). PV holds a Methusalem grant (BOF09/01M00709) from the Flemish Government. MB has a tenure track position within Multidisciplinary Research Program from the Ghent University (GROUP-ID).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S Fulda.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Löder, S., Fakler, M., Schoeneberger, H. et al. RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia 26, 1020–1029 (2012). https://doi.org/10.1038/leu.2011.353

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2011.353

Keywords

This article is cited by

Search

Quick links